Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 182

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Incidence and Predictive Factors for Infectious Disease after Rituximab Therapy in Kidney‐Transplant Patients

Open access
Kamar, N., Milioto, O., Puissant‐Lubrano, B., Esposito, L., Pierre, M.C., Mohamed, A.Ould, Lavayssière, L., Cointault, O., Ribes, D., Cardeau, I., Nogier, M.B., Durand, D., Abbal, M., Blancher, A., Rostaing, L. · 2010 · American Journal of Transplantation

Abstract

Rituximab off-label use includes organ transplantation. We review the occurrence of infectious disease and its outcome after rituximab therapy. Between April 2004 and August 2008, 77 kidney-transplant patients received rituximab therapy [2-8 courses (median 4) of 375 mg/m2 each] for various reasons. Their results were compared with a control group (n=902) who had received no rituximab. After a median follow-up of 16.5 (1-55) months for rituximab patients and 60.9 (1.25-142.7) months for control patients, the incidence of infectious disease was 45.45% and 53.9% (ns), respectively. The incidence of bacterial infection was similar between the two groups, whereas the viral-infection rate was significantly lower, and the rate of fungal infection was significantly higher in the rituximab group. Nine out of 77 patients (11.68%) died after rituximab therapy, of which seven deaths (9.09%) were related to an infectious disease, compared to 1.55% in the controls (p=0.0007). In the whole population, the independent predictive factors for infection-induced death were the combined use of rituximab and antithymocyte-globulin given for induction or anti-rejection therapy, recipient age, and bacterial and fungal infections. After kidney transplantation, the use of rituximab is associated with a high risk of infectious disease and death related to infectious disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1600-6143.2009.02785.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 182

Metadata

Authors
Kamar, N., Milioto, O., Puissant‐Lubrano, B., Esposito, L., Pierre, M. C., Mohamed, A. O., Lavayssière, L., Cointault, O., Ribes, D., Cardeau, I., Nogier, M. B., Durand, D., Abbal, M., Blancher, A., & Rostaing, L.
Venue
American Journal of Transplantation
Publisher
Elsevier BV
Published
2010-01
Volume
10
Issue
1
Pages
89-98
ISSN
1600-6135 (ISSN-L)
OpenAlex
W1510382284
Cited by
182
References
1
FWCI
10.49
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Incidence and Predictive Factors for Infectious Disease after Rituximab Therapy in Kidney‐Transplant Patients. https://app.cochat.ai/papers/10.1111/j.1600-6143.2009.02785.x
The paper
Kamar, N., Milioto, O., Puissant‐Lubrano, B., Esposito, L., Pierre, M. C., Mohamed, A. O., Lavayssière, L., Cointault, O., Ribes, D., Cardeau, I., Nogier, M. B., Durand, D., Abbal, M., Blancher, A., & Rostaing, L. (2010). Incidence and Predictive Factors for Infectious Disease after Rituximab Therapy in Kidney‐Transplant Patients. American Journal of Transplantation. https://doi.org/10.1111/j.1600-6143.2009.02785.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.